

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.
Please cancel all previously-pending claims and enter new claims 20-22.

Listing of Claims:

1.- 19. (canceled)

20. (New) A method of determining predisposition to serum cholesterol elevation of greater than 239 mg/dL in a human patient upon treatment with everolimus comprising:

a) assaying a blood sample from the patient for the presence of a cytosine (C) at polymorphic site -31 of the IL-1 β gene, which is position 1903 of SEQ ID NO 11; and

b) determining that the patient has a predisposition to serum cholesterol elevation of greater than 239 mg/dL upon treatment with everolimus by the presence of a C at the polymorphic site -31 of the human IL-1 β gene.

21. (New). A method of treating a human patient with everolimus comprising:

a) assaying a blood sample from the patient for a thymine (T) or cytosine (C) at polymorphic site -31 of the human IL-1 β gene, which is position 1903 of SEQ ID NO 11; and

b) treating the patient with everolimus if the patient has a T for both alleles at the polymorphic site -31 of the human IL-1 β gene or treating the patient with everolimus and an alternative treatment if the patient has a C allele at the polymorphic site -31 of the human IL-1 β gene.

22. (New) The method of claim 21, wherein the alternative treatment comprises a cholesterol lowering medication selected from the group consisting of a bile acid sequestrant, a fibric acid derivative, an HMG-CoA reductase inhibitor, and nicotinic acid.